Tiny study aims to Fine-Tune antibody therapy for rare immune disorders
NCT ID NCT07516002
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 15 people with primary antibody immunodeficiency who are receiving immunoglobulin therapy. Researchers will track changes in specific immune cells (T and B cells) and infection rates over time. The goal is to see if these cell changes can help predict how well the therapy is working, potentially leading to more personalized treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- immunoglobulin (antibody replacement therapy)
- What this could lead to
- If successful, this could help doctors better tailor immunoglobulin therapy for patients with antibody immunodeficiency by tracking specific immune cell changes.
- What could go wrong
- This is a very small, early-stage observational study with only 15 participants, so results may not apply broadly. It focuses on measuring immune markers, not on proving a new treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY IMMUNODEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.